查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
急性腎損傷 (AKI) 治療市場 – 2023 年至 2028 年預測
市場調查報告書
商品編碼
1295377

急性腎損傷 (AKI) 治療市場 – 2023 年至 2028 年預測

Acute Kidney Injury (AKI) Disease Treatment Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 132 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

急性腎損傷 (AKI) 治療市場預計複合年增長率為 2.63%，從 2021 年的 310.7 億美元增至 2028 年的 372.53 億美元。

全球急性腎損傷治療市場受到急性腎損傷發病率上升的顯著影響。 美國國家腎臟基金會估計，美國大約有 3700 萬人患有腎臟疾病。 由於衰老、不良飲食習慣和大量飲酒，腎臟受損的風險正在增加。 對乙□氨基酚和其他藥物過量、肝炎、自身免疫性疾病和代謝性疾病也是導致市場爆炸的因素。 此外，不斷上漲的醫療保健成本和政府改善醫療保健系統的措施預計將增加市場收入。 然而，透析服務的高成本和患者對長期治療計劃的依從性低正在阻礙市場擴張。

與生活方式相關的疾病迅速增加

急性腎損傷是腎功能突然暫時喪失。 這種情況可能是由於糖尿病或高血壓等一些潛在疾病引起的。 由於人們生活方式的改變，許多疾病不斷出現。 典型的例子包括糖尿病、肥胖症、高血壓以及與肝臟和腎臟有關的疾病。 世界衛生組織 (WHO) 估計，影響一個人的健康和生活質量的變量中有 60% 與其生活方式有關。 人們的健康受到加工食品、垃圾食品和不良飲食習慣的影響。 此外，缺乏鍛煉或缺乏身體活動會增加消化不良和隨後的急性腎損傷的風險。 人們越來越沉迷於毒品、酒精和吸煙，所有這些都會對健康產生負面影響。 缺乏身體活動和缺乏鍛煉也會增加消化不良和相關急性腎損傷的可能性。 人們沉迷於酒精、吸煙和毒品，這也對健康產生負面影響。 例如，國際腎髒病學會估計全球每年發生超過 1330 萬例急性腎損傷病例。 此外，全世界每年有 170 萬人死於急性腎損傷。 在美國，大約 1% 的住院患者患有 AKI。

此外，政府加速醫□□療保健創新的舉措也正在加速市場擴□□張。

根據國家科學基金會和白宮科學技術政策辦公室的公告，國家人工智能研究資源工作組於 2021 年 6 月成立。 該工作組將製定擴大教育資源和基本工具的路線圖，以促進全國范圍內的人工智能創新。 此外，行業領先公司正專注於開發急性腎損傷治療藥物，預計這將在預測期內推動全球急性腎損傷治療市場的增長。

按 RRT 類型，急性腎損傷治療市場分為持續性 RRT 和間歇性 RRT。

與間歇性 RRT 不同，連續透析以緩慢、恆定的速度從血液中去除水分和廢物，從而降低了血流動力學不穩定的患者無法耐受這種去除的風險。 儘管這種類型的 RRT 更適合治療 AKI，但在許多經濟體中，高成本仍然是採用 CRRT 的主要障礙，因為這些經濟體的目標是負擔得起昂貴的醫療程序。

CRRT 在 AKI 治療市場的增長也得到了醫療培訓計劃和教育計劃的支持。 腎髒病專家、重症監護醫師和重症監護護士等醫療保健專業人員接受了有關實施 CRRT 的原則和實踐方面的培訓和教育。 訓練有素的醫務人員為 CRRT 在臨床實踐中的廣泛採用和成功做出了貢獻。

北美和歐洲將在 2021 年佔據很大的市場份額。

按地區劃分，全球 AKI 疾病治療市場分為北美、南美、歐洲、中東和非洲以及亞太地區。 由於中國和印度等國家慢性病病例的增加，以及該地區醫療旅遊業的蓬勃發展，亞太地區在預測期內將出現強勁的複合年增長率。看來會的。

在北美，美國糖尿病的高患病率正在增加急性腎損傷患者的數量。 據美國疾病控制與預防中心 (CDC) 稱，AKI 是美國的一個重大公共衛生問題，每年影響超過 50 萬人，並導致超過 10 萬人死亡。 AKI 還與醫療費用增加有關，美國每年 AKI 住院費用估計為 100 億美元。

此外，腎臟替代療法 (RRT)（包括血液透析和腹膜透析）等創新療法的採用正在增加。 這些治療方法變得越來越廣泛且負擔得起，使更多患者能夠獲得所需的護理。

市場趨勢：

  • 2021 年9 月，Sentien Biotechnologies, Inc.（一家開發新型細胞療法的臨床階段技術進步公司）被宣布成為生物醫學科學部的成員，生物醫學科學部是美國負責準備和響應的助理部長的下屬部門。衛生與公眾服務部：我們與高級研究與發展局 (BARDA) 合作，宣布將在急性腎損傷患者中測試 Sentien 的體外細胞療法 SBI-101。
  • 醫療器械、服務和解決方案領域的全球領導者美敦力公司 (Medtronic plc) 於 2020 年 12 月宣佈在美國正式推出 Carpe Diem 心臟腎小兒透析急救設備。 Carpe Diem 系統是同類產品中第一個被推薦用於因急性腎損傷或液體超負荷而需要血液透析或血液濾過治療的患者的系統。 專為體重 2.5-10 公斤的患者進行長期腎臟替代治療而設計。

內容

第 1 章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場細分
  • 貨幣
  • 先決條件
  • 基準年和預測年的時間表

第 2 章研究方法

  • 調查數據
  • 調查過程

第 3 章執行摘要

  • 研究亮點

第 4 章市場動態

  • 市場促進因素
  • 市場抑制因素
  • 波特五力分析
  • 行業價值鏈分析

第 5 章急性腎損傷治療市場：按組成部分

  • 簡介
  • 治療
    • 藥物類型
    • 透析
  • 診斷
    • 尿液分析
    • 驗血
    • 腎小球濾過率 (GFR)
    • 圖像檢查
    • 腎活檢

第 6 章急性腎損傷治療市場：按 RRT 類型劃分

  • 簡介
  • 持久
  • 間歇性

第 7 章急性腎損傷治療市場：按地區

  • 簡介
  • 北美
    • 按組件
    • 按 RRT 類型
    • 按國家/地區
  • 南美洲
    • 按組件
    • 按 RRT 類型
    • 按國家/地區
  • 歐洲
    • 按組件
    • 按 RRT 類型
    • 按國家/地區
  • 中東和非洲
    • 按組件
    • 按 RRT 類型
    • 按國家/地區
  • 亞太地區
    • 按組件
    • 按 RRT 類型
    • 按國家/地區

第 8 章競爭格局與分析

  • 主要公司及戰略分析
  • 新興公司和市場盈利能力
  • 合併、收購、協議和合作
  • 供應商競爭力矩陣

第 9 章公司簡介

  • Exponential Biotherapies, Inc.
  • Nikkiso America, Inc.
  • Am-Pharma
  • Renalguard Solutions, Inc.
  • Angion Biomedica Corp.
  • Thrasos Therapeutics Inc.
  • Atoxbio
  • Sentien Biotechnologies, Inc
簡介目錄
Product Code: KSI061612284

The Acute Kidney Injury (AKI) disease treatment market is predicted to grow at a CAGR of 2.63% from US$31.070 billion in 2021 to US$37.253 billion by 2028.

The global market for acute kidney injury treatment is significantly influenced by the rising incidence of acute kidney damage. The National Kidney Foundation estimates that kidney illnesses impact about 37 million people in the US. Kidney injury risk has increased because of an aging population, poor diet, and heavy alcohol use. Acetaminophen and other drug overdoses, hepatitis, autoimmune disorders, and metabolic diseases are other causes contributing to the market's explosive expansion. Additionally, it is projected that rising healthcare costs and government measures to improve the healthcare system will boost market revenue. However, the market expansion is being hampered by the high cost of dialysis services and the low compliance from patients for long-term treatment plans.

The surge in lifestyle diseases.

Acute kidney injury results in sudden and temporary loss of the function of the kidney. This could occur due to several underlying diseases like diabetes and high blood pressure. A slew of diseases is cropping up due to changing lifestyles of people. Some of the prominent examples are diabetes, obesity, hypertension, and other liver or kidney-related diseases. The World Health Organization estimates that 60% of the variables affecting a person's health and quality of life are related to their way of living. People's health is being impacted by processed and junk food as well as poor eating habits. Additionally, a lack of exercise and movement increases the risk of dyspepsia and subsequent acute renal damage. People are developing addictions to drugs, alcohol, and smoking, all of which have detrimental effects on their health. Lack of physical movement and exercise is also increasing the likelihood of indigestion and consequent acute kidney injuries. People are getting addicted to alcohol, smoking, and drugs which also have adverse implications for their health. For instance, the International Society of Nephrology estimates that there are over 13.3 million cases of acute renal damage each year throughout the world. Globally, acute renal damage also results in 1.7 million deaths each year. AKI is present in about 1% of hospitalized patients in the United States.

Further, government efforts to speed up healthcare innovation are also accelerating market expansion.

The National Artificial Intelligence Research Resource Task Force was established in June 2021 as a result of an announcement made by the National Science Foundation and the White House Office of Science and Technology Policy. This task force will develop a roadmap for the expansion of educational resources and essential tools that will promote Al innovation across the country. Moreover, the industry's leading players are concentrating on the development of acute renal injury therapies, which is anticipated to propel the growth of the worldwide acute kidney injury treatment market during the forecast period.

By type of RRT, the AKI disease treatment market has been segmented into continuous and intermittent.

Unlike intermittent RRT, continuous dialysis involves the removal of water and waste from the blood takes place at a slow and steady rate which reduces the risk of this removal being poorly tolerated by patients who are hemodynamically unstable. Although this type of RRT is better suited for the treatment of AKI, their higher cost continues to be a major factor hindering their adoption across many economies where the affordability of expensive medical procedures is still a goal.

The growth of CRRT in the AKI treatment market is also supported by medical training programs and educational initiatives. Healthcare professionals, including nephrologists, intensivists, and critical care nurses, receive training and education on the principles and practical aspects of performing CRRT. Well-trained medical staff contributes to the wider adoption and successful implementation of CRRT in clinical settings.

North America and Europe held a significant market share of the market in 2021.

By geography, the global AKI disease treatment market is segmented as North America, South America, Europe, the Middle East and Africa, and Asia Pacific. APAC will witness a significant CAGR during the forecast period owing to the rising cases of chronic diseases in countries like China and India, along with the booming medical tourism industry across the region.

In North America, the high prevalence of diabetes in the U.S. is increasing the number of people with acute kidney injury. According to the Centers for Disease Control and Prevention (CDC), AKI is a significant public health problem in the United States, affecting over 500,000 people each year and resulting in more than 100,000 deaths. AKI is also associated with increased healthcare costs, with hospitalizations for AKI costing an estimated $10 billion annually in the US.

Moreover, there is increasing adoption of innovative treatment options, such as renal replacement therapies (RRTs), which include hemodialysis and peritoneal dialysis. These treatments are becoming more widely available and affordable, allowing more patients to access the care they need.

Market Developments:

  • In September 2021, Sentien Biotechnologies, Inc., a clinical-stage technological advancement company developing novel cell therapy methods, announced a collaboration with the biomedical field Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services Assistant Secretary for Preparedness and Response, to test Sentien's ex vivo cell therapy, SBI-101, in patients with acute kidney injuries.
  • The official introduction of the Carpediem cardio-renal pediatric dialysis emergency machine in the United States was announced by Medtronic plc, a world leader in medical equipment, services, and solutions, in December 2020. The first of its type Carpediem system is recommended for use in patients needing hemodialysis or hemofiltration therapy due to acute renal damage or fluid overload. It is designed to give patients who weigh between 2.5 and 10 kilograms continuous renal replacement treatment.

Market Segmentation:

By Component

  • Treatment
  • Drug Type
  • Isotonic Solution
  • Antibiotic
  • Others
  • Dialysis
  • Diagnosis
  • Urine Tests
  • Blood Tests
  • Glomerular Filtration Rate (GFR)
  • Imaging tests
  • Kidney Biopsy

By Type of RRT

  • Continuous
  • Intermittent

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY COMPONENT

  • 5.1. Introduction
  • 5.2. Treatment
    • 5.2.1. Drug Type
    • 5.2.1.1. Isotonic Solution
    • 5.2.1.2. Antibiotic
    • 5.2.1.3. Others
    • 5.2.2. Dialysis
  • 5.3. Diagnosis
    • 5.3.1. Urine Test
    • 5.3.2. Blood Test
    • 5.3.3. Glomerular Filtration Rate (GFR)
    • 5.3.4. Imaging Test
    • 5.3.5. Kidney Biopsy

6. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY TYPE OF RRT

  • 6.1. Introduction
  • 6.2. Continuous
  • 6.3. Intermittent

7. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Component
    • 7.2.2. By Type of RRT
    • 7.2.3. By Country
    • 7.2.3.1. USA
    • 7.2.3.2. Canada
    • 7.2.3.3. Mexico
  • 7.3. South America
    • 7.3.1. By Component
    • 7.3.2. By Type of RRT
    • 7.3.3. By Country
    • 7.3.3.1. Brazil
    • 7.3.3.2. Argentina
    • 7.3.3.3. Others
  • 7.4. Europe
    • 7.4.1. By Component
    • 7.4.2. By Type of RRT
    • 7.4.3. By Country
    • 7.4.3.1. Germany
    • 7.4.3.2. France
    • 7.4.3.3. United Kingdom
    • 7.4.3.4. Spain
    • 7.4.3.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. By Component
    • 7.5.2. By Type of RRT
    • 7.5.3. By Country
    • 7.5.3.1. Saudi Arabia
    • 7.5.3.2. UAE
    • 7.5.3.3. Israel
    • 7.5.3.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. By Component
    • 7.6.2. By Type of RRT
    • 7.6.3. By Country
    • 7.6.3.1. China
    • 7.6.3.2. Japan
    • 7.6.3.3. South Korea
    • 7.6.3.4. India
    • 7.6.3.5. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. Exponential Biotherapies, Inc.
  • 9.2. Nikkiso America, Inc.
  • 9.3. Am-Pharma
  • 9.4. Renalguard Solutions, Inc.
  • 9.5. Angion Biomedica Corp.
  • 9.6. Thrasos Therapeutics Inc.
  • 9.7. Atoxbio
  • 9.8. Sentien Biotechnologies, Inc